Ascendis Pharma to Directly List Ordinary Shares on Nasdaq, Mandating ADS Exchange
Summary
Ascendis Pharma announced plans to directly list its ordinary shares on The Nasdaq Global Select Market, effective April 20, 2026, requiring a mandatory exchange of all outstanding American Depositary Shares (ADSs) for ordinary shares.
Key Events
-
Direct Nasdaq Listing
Ascendis Pharma plans to list its ordinary shares directly on The Nasdaq Global Select Market, effective April 20, 2026.
-
Mandatory ADS Exchange
All outstanding American Depositary Shares (ADSs) will be mandatorily exchanged for one ordinary share each.
-
Trading Transition
The last day of ADS trading on Nasdaq is expected to be April 17, 2026, with ordinary shares commencing trading on April 20, 2026, under the ticker ASND.
Analysis
This strategic move simplifies Ascendis Pharma's capital structure for U.S. investors by eliminating the American Depositary Share (ADS) program. The direct listing of ordinary shares on Nasdaq is anticipated to enhance liquidity, reduce administrative complexities and fees associated with ADSs, and potentially broaden the company's investor base. Investors currently holding ADSs will automatically receive ordinary shares, which will continue to trade under the existing ticker symbol ASND.
At the time of this filing, ASND was trading at $233.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5B. The 52-week trading range was $124.06 to $248.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.